Critical Review: Heyu Biological Technology (OTCMKTS:HYBT) and Nexalin Technology (NASDAQ:NXL)

Heyu Biological Technology (OTCMKTS:HYBT) and Nexalin Technology (NASDAQ:NXL) are both small-cap computer and technology companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation and institutional ownership.

Risk & Volatility

Heyu Biological Technology has a beta of -17.74, indicating that its share price is 1,874% less volatile than the S&P 500. Comparatively, Nexalin Technology has a beta of 5.42, indicating that its share price is 442% more volatile than the S&P 500.

Institutional & Insider Ownership

0.7% of Nexalin Technology shares are held by institutional investors. 89.2% of Heyu Biological Technology shares are held by insiders. Comparatively, 27.7% of Nexalin Technology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Heyu Biological Technology and Nexalin Technology’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heyu Biological Technology	$80,000.00	287.28	-$270,000.00	N/A	N/A
Nexalin Technology	$1.32 million	7.89	-$1.70 million	N/A	N/A

Heyu Biological Technology has higher earnings, but lower revenue than Nexalin Technology.

Analyst Ratings

This is a summary of recent ratings and target prices for Heyu Biological Technology and Nexalin Technology, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heyu Biological Technology	0	0	0	0	N/A
Nexalin Technology	0	0	0	0	N/A

Profitability

This table compares Heyu Biological Technology and Nexalin Technology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Heyu Biological Technology	-453.55%	-6.43%	-4.43%
Nexalin Technology	-3,576.32%	-105.41%	-80.04%

Summary

Heyu Biological Technology beats Nexalin Technology on 6 of the 9 factors compared between the two stocks.

About Heyu Biological Technology

Hong Chang Biotechnologies (HK) Limited was incorporated in 2023 and is based in Kowloon, Hong Kong. Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Zengqiang Investment Limited. As of September 4, 2023, Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Heyu Biological Technology Corporation.

About Nexalin Technology

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. In addition, it designs and develops Generation 2 and Generation 3, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, Alzheimer's disease, and dementia. The company is based in Houston, Texas.